NCT01881113View on ClinicalTrials.gov

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Allergic Conjunctivitis
Interventions
DRUG

AC-170 0.24%

1 drop in each eye at 2 separate times during a 14 day period

DRUG

AC-170 0%

1 drop in each eye at 2 separate times during a 14 day period

Trial Locations (1)

01810

Ora, Inc., Andover

Sponsors
All Listed Sponsors
lead

Aciex Therapeutics, Inc.

INDUSTRY

NCT01881113 - A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle | Biotech Hunter | Biotech Hunter